We love to hear from our listeners. Send us a message. On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to discuss how the FDA is increasing flexibility in cell and gene therapy development without lowering evidentiary standards, emphasizing a risk-based, holistic approach. They also explore what this means for developers, from platform strategies and global regulatory divergence to the growing role of patient advocacy and...
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Rewriting Disease Biology Through LSD1 Inhibition with Oryzon's Carlos Buesa, Ph.D.
Advancing Early Detection in Rare Cancers with Catriona Jamieson, M.D., Ph.D.
Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye
Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous
Free AI-powered recaps of Cell & Gene: The Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.